4 completed, 2 active not recruiting, 2 not yet recruiting, 1 recruiting. 10 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 4, Active not recruiting 2, Not yet recruiting 2, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 1 | Not yet recruiting | Banu Aji Dibyasakti | 64 | 2026-08-30 | 2026-08-13 |
| A Study of IBI3031 in Participants With Thyroid Eye Disease IBI3031, placebo - Thyroid Eye Disease | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 66 | 2026-06-30 | 2026-07-14 |
| An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) NTB003, NTB003 and Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 74 | 2026-03-01 | 2026-03-10 |
| Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) Kamuvudine-9 - Thyroid Eye Disease | Phase 1 | Terminated | Peter Timoney | 4 | 2024-11-06 | 2026-04-01 |
| A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease Lu AG22515 - Thyroid Eye Disease | Phase 1 | Active not recruiting | H. Lundbeck A/S | 20 | 2024-09-19 | 2026-09-09 |
| A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease AMG 732, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Active not recruiting | Amgen | 94 | 2024-05-30 | 2026-08-10 |
| Study of ZB001 in Chinese Patients With Thyroid Eye Disease ZB001 for injection - Thyroid Eye Disease | Phase 1 | Completed | Zenas BioPharma (USA), LLC | 17 | 2023-05-10 | 2025-04-11 |
| Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) lonigutamab, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | ACELYRIN Inc. | 31 | 2023-02-14 | 2025-07-01 |
| A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease Teprotumumab - Thyroid Eye Disease | Phase 1 | Completed | Amgen | 16 | 2022-07-14 | 2024-06-21 |
| A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease LASN01, Placebo - Pulmonary Fibrosis, Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | Lassen Therapeutics 1 PTY LTD | 75 | 2022-06-06 | 2024-12-30 |
Graves Ophthalmopathy (10) · Pulmonary Fibrosis (1)
Autoimmune Diseases (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Endocrine System Diseases (10) · Exophthalmos (10) · Eye Diseases (10) · Eye Diseases, Hereditary (10) · Genetic Diseases, Inborn (10) · Goiter (10) · Graves Disease (10) · Hyperthyroidism (10) · Immune System Diseases (10) · Orbital Diseases (10) · Thyroid Diseases (10) · Fibrosis (1) · Lung Diseases (1)
Atorvastatin (1) · Injections (1) · Methylprednisolone (1) · teprotumumab (1)
Amgen (2) · ACELYRIN Inc. (1) · Banu Aji Dibyasakti (1) · H. Lundbeck A/S (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Lassen Therapeutics 1 PTY LTD (1) · Nanjing Chia-tai Tianqing Pharmaceutical (1) · Peter Timoney (1) · Zenas BioPharma (USA), LLC (1)
United States (4) · Australia (3) · China (2) · Poland (2) · Bosnia and Herzegovina (1) · Bulgaria (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · Indonesia (1) · Italy (1) · Japan (1) · Singapore (1)
Peter Timoney (1)
2023 (1)